BioCentury
ARTICLE | Company News

Miltenyi Biotec, Stemgent deal

May 17, 2010 7:00 AM UTC

Miltenyi received exclusive rights to commercialize Stemgent's existing stem cell product portfolio outside the U.S. Stemgent markets viral-delivered transcription factors, cell lines, antibodies, sma...